Richard Dubinsky, MD
Neurology · Kansas City, KSNPI 1205933892
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,675 of the $121,961 with a category attached, or 98.1%. AbbVie accounts for 99.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $31,558 and has fallen 69.0% since, to $9,785 in 2025. Among neurology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $1060.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$122K
- Genentech USA, Inc.$91
- GRT US Holding, Inc.$90
- Argenx US, Inc.$36
- Boston Scientific$35
- Amylyx Pharmaceuticals, Inc.$19
- plus $70 from 5 others
Across 58 payments — averaging $2395.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$132K
- Neurocrine Biosciences, Inc.$7K
What the payments were for
- Speaking & faculty fees$119,67598%
- Travel & lodging$9121%
- Food & beverage$1,3741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $121,619 |
| Genentech USA, Inc. | 1 | $91 |
| GRT US Holding, Inc. | 5 | $90 |
| Argenx US, Inc. | 2 | $36 |
| Boston Scientific | 1 | $35 |
| Amylyx Pharmaceuticals, Inc. | 1 | $19 |
| Avion Pharmaceuticals | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$120,951
How this compares
$121,961 in reported general payments places this provider in the 95th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 118 | $846,949 |
| IngrezzaValbenazine Tosylate | 102 | $824,926 |
| AustedoDeutetrabenazine | 76 | $588,888 |
| SkyclarysOmaveloxolone | 18 | $580,896 |
| NuplazidPimavanserin Tartrate | 38 | $219,907 |
| Tetrabenazine | 59 | $176,465 |
| RytaryCarbidopa/Levodopa | 42 | $31,029 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 652 | $26,797 |
| Entacapone | 57 | $12,721 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 100 | $10,381 |
| Baclofen | 154 | $5,963 |
| Clonazepam | 507 | $5,350 |
| Gabapentin | 125 | $5,317 |
| Ropinirole Hcl | 154 | $4,954 |
| Primidone | 156 | $3,395 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
- Patrick LandazuriKansas City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.